China to block Chinese firms from investing in the U.S. amid tariff war; Shenzhen launches incentives for foreign-owned hospitals following national legislation; and U.S. companies plan continuous engagement with China
China’s draft pharmaceutical trial rules aim to balance innovation with drug availability; CAC issues first rules to regulate facial recognition technology; and UBS becomes the 5th wholly foreign-owned securities firm in China.
Jianwei (Jerry) Fang, Xiaoyu (Arthur) Jin and Haoyi Sun of Zhong Lun Law Firm discuss the reasons behind, and the implications of, Illumina’s inclusion in China’s Unreliable Entity List, as well as compliance recommendations for multinational corporations
China strengthens Anti-Foreign Sanctions Law in response to U.S. restrictions; Chinese firms move production facilities overseas amidst key economic changes; and China introduces regulations to protect interests in overseas IP disputes
Multinationals must comply with new Chinese labeling requirements while the U.S. and EU have other specifications; A second Chinese court ruling affirms AI-generated images have copyright protection; and Supreme People’s Court cracks down on fraudulent behavior of prepayment service providers
Chinese regulatory support to China originated-biopharma companies is going global. Wu Ting, partner of the Life Sciences and Healthcare Practice at Haiwen & Partners examines the implications
Chinese EV maker Geely expands into Brazil through a partnership with France’s Renault; The parent company of Calvin Klein and Tommy Hilfiger is blacklisted by China; and Canadian Solar is sued by China’s Trina Solar over patent infringement.
